The latest announcement is out from Asensus Surgical (ASXC).
On August 22, 2024, a significant merger was finalized, resulting in the involved company becoming a wholly owned subsidiary, with common stockholders receiving $0.35 per share in cash. Stock options and unvested shares were also converted to cash rights, adhering to existing vesting terms. The company’s board underwent changes, with resignations and new appointments occurring immediately after the merger. Concurrently, the company’s corporate documents were amended, and it initiated the process to delist its common stock from the NYSE American, signaling the end of an era and the beginning of a new chapter under the merger agreement’s stipulations.
Learn more about ASXC stock on TipRanks’ Stock Analysis page.
